Pregnancy exposure to environmental phenols and breastfeeding duration in the HOME Study

Zaya Gerili1, Joseph M Braun2, Kimberly Yolton3

  • 1National Institute of Public Health, University of Southern Denmark, Denmark.

Environmental phenols are endocrine-disrupting chemicals widely used in personal care products. They have been shown to affect the mammary gland, but knowledge about their impact on breastfeeding duration is limited. We aimed to explore associations between maternal phenols exposure during pregnancy and breastfeeding duration. We included 373 mother-infant pairs from the Health Outcomes and Measures of the Environment (HOME) Study (Cincinnati, Ohio, USA) enrolled from 2003 to 2006. We measured urinary concentrations of eight phenols at 16 and 26 weeks of gestation (bisphenol A, triclosan, benzophenone-3, 2,4-/2,5-dichlorophenols, methyl-/propyl-/butyl-paraben) and collected breastfeeding information until mothers reported discontinuation of exclusive and any breastfeeding. We assessed the hazard ratios (HRs) and odds ratios (ORs) of the cessation of breastfeeding in relation to the eight phenols using confounder adjusted Cox proportional hazards and logistic regression models, respectively. In adjusted Cox regression models, each doubling of urinary triclosan concentration was associated with HRs of 1.09 (95% CI: 1.00, 1.18) for any breastfeeding cessation within 6 months, and 1.08 (95% CI: 0.96, 1.21) for cessation between 6 and 12 months, with tertile-categorized analyses suggesting a dose-response relationship for cessation within 6 months. We did not observe consistent associations with breastfeeding duration for the seven other phenols, but each doubling concentrations in triclosan and BP-3 were associated with 18% (95% CI: 3, 35%) and 13% (95% CI: 1, 26%), respectively, higher odds of terminating breastfeeding earlier than intended. Considering the limited sample size and multiple testing, our findings need to be confirmed in larger studies.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
341
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
762
Development of the Oral Microbiota01:28

Development of the Oral Microbiota

The establishment of the oral microbiome begins before birth, challenging the long-held belief that the fetal oral cavity is sterile. The presence of oral microbes such as Streptococcus and Fusobacterium in amniotic fluid suggests that microbial exposure may occur in utero, potentially through translocation from the maternal oral or gastrointestinal tract. This early colonization primes the neonatal immune system and sets the stage for subsequent microbial succession. Maternal health,...
38
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
484
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.6K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
378